Modulating Immune Responses in Muscle Gene Therapy
Publisher
Springer New York
Reference87 articles.
1. Arruda, V.R., Schuettrumpf, J., Herzog, R., Nichols, T., Robinson, N., Lotfi, Y., Mingozzi, F., Xiao, W., Couto, L., and High, K. (2004). Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103, 85–92. 2. Arruda, V. R. (2006). Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models. J Thromb Haemost 4, 1215–1217. 3. Arruda, V. R., Stedman, H. H., Nichols, T. C., Haskins, M. E., Nicholson, M., Herzog, R. W., Couto, L. B., and High, K. A. (2005). Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 3458–3464. 4. Banks, G. B., and Chamberlain, J. S. (2008). The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol 84, 431–453. 5. Bish, L. T., Sleeper, M. M., Brainard, B., Cole, S., Russell, N., Withnall, E., Arndt, J., Reynolds, C., Davison, E., Sanmiguel, J., et al. (2008). Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther 16, 1953–1959.
|
|